2025/06/27 by Ella J. Baker, Greg Cumberford, Patrick Hanaway · 1 citation
Agricultural and Biological Sciences · Biochemistry, Genetics and Molecular Biology · Nursing · #Aquaculture Nutrition and Growth #Eicosanoids and Hypertension Pharmacology #Fatty Acid Research and Health
paper · pdf · doi:10.1002/lipd.12452
crossref issued 2025/06/27 · crossref published 2025/06/27 · crossref published-online 2025/06/27 · openalex publication_date 2025/06/27 · crossref created 2025/06/27 · openalex created_date 2025/10/10 · crossref published-print 2025/11/01 · crossref deposited 2025/11/12 · crossref indexed 2026/07/31 · openalex updated_date 2026/08/01
Long-chain (LC) omega-3 polyunsaturated fatty acids (PUFAs) like eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) are crucial for optimal development, healthy aging, and disease management. Traditionally sourced from fatty fish, these omega-3 PUFAs face sustainability challenges, prompting increased exploration of plant-based alternatives, such as stearidonic acid (SDA). Recent studies highlight the efficient conversion of SDA to EPA, meaning that SDA may offer similar health benefits to EPA, including immune, joint, cognitive, and gut microbiome modulation (with distinct SDA-derived metabolites). This mini-review explores new research on SDA and its potential to deliver human health benefits. SDA-rich oils, notably Buglossoides arvensis oil (RBO; also known as Ahiflower oil) provide an eco-friendly, sustainable alternative to fish-derived omega-3 PUFAs. As concerns about marine omega-3 PUFA sources grow, SDA-rich oils present a viable option for clinicians and consumers seeking effective omega-3 PUFA supplementation.